PCT to provide development, manufacturing services to Adaptimmune

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Role of CDMOs in Outsourced Pharmaceutical Manufacturing

The pharmaceutical sector stands at the crossroads of innovation...

Regional Pharma Hubs for Effective Supply Chain Outcomes

It is well to be noted that the pharmaceutical...

Incorporation of Antimicrobial Coatings in Pharmaceuticals

In the very rapidly evolving pharmaceutical spectrum, the safeguarding...

Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, has signed an agreement to provide cell product development and manufacturing services for Adaptimmune’s clinical trials.

Adaptimmune will make use of PCT services in the development of its NYESO-1c259-T cell therapy targeting various oncology indications.

Adaptimmune chief executive officer James Noble said, “With our sights set on future pivotal trials for our T cell therapy products, we have invested significant effort towards establishing capabilities within Adaptimmune that support expansion of our clinical platform in terms of both scale and compliance with FDA requirements beyond phase I/II.”

PCT facility in Allendale, New Jersey, will provide transfer and qualification services essential for the NYESO-1c259-T cell therapy product manufacturing process following manufacturing of the product.

PCT president and chief scientific officer Robert Preti said, “Given our extensive experience with technology transfer, process qualification and GMP manufacturing, we feel PCT will be an asset to Adaptimmune as it develops its product for the U.S. commercial market.”

Latest stories

Related stories

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Role of CDMOs in Outsourced Pharmaceutical Manufacturing

The pharmaceutical sector stands at the crossroads of innovation...

Regional Pharma Hubs for Effective Supply Chain Outcomes

It is well to be noted that the pharmaceutical...

Incorporation of Antimicrobial Coatings in Pharmaceuticals

In the very rapidly evolving pharmaceutical spectrum, the safeguarding...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back